Key Points {#FPar1}
==========

Subjects who developed anti-drug antibodies (ADAs) to bococizumab are unlikely to develop clinically relevant cross-reactivity to marketed anti-proprotein convertase subtilisin/kexin type-9 (PCSK9) monoclonal antibodies. This is based on the weak and transient cross-reactivity signal observed in 0.6% (1/155) of the subjects evaluated.ADA cross-reactivity was evaluated using a novel ADA assay approach within the context of a single validated assay that helped minimize problems associated with assessing cross-reactivity in separate assays. This approach may be applicable to other biotherapeutics where cross-reactivity of ADA is a potential concern, especially for those within the same therapeutic class.

Introduction {#Sec1}
============

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has an essential role in the biology of low-density lipoprotein (LDL) cholesterol (LDL-C), and in the past few years monoclonal antibodies (mAbs) against PCSK9 have become an important addition to the physicians' armamentarium for the management of dyslipidemia \[[@CR1], [@CR2]\]. PCSK9 binds to the LDL receptor, resulting in its degradation and an increase in circulating levels of LDL-C \[[@CR3], [@CR4]\]. The importance of PCSK9 has been demonstrated by studying genetic mutations. For example, loss-of-function mutations are associated with decreased LDL-C levels and reduced coronary heart disease events \[[@CR5]\], whereas gain-of-function mutations in *PCSK9* cause familial hypercholesterolemia (FH), a condition associated with high LDL-C levels and elevated cardiovascular risk \[[@CR6], [@CR7]\]. Antibodies targeted against PCSK9 result in a higher density of LDL receptors at the surface of hepatocytes and ultimately this lowers LDL-C \[[@CR8], [@CR9]\]. Two fully human anti-PCSK9 mAbs (alirocumab, evolocumab) are approved for use alongside dietary changes and other lipid-lowering agents to reduce LDL-C levels in patients with FH or atherosclerotic cardiovascular disease \[[@CR10], [@CR11]\].

Bococizumab is a humanized IgG2Δa mAb targeting the LDL receptor-binding domain of PCSK9 \[[@CR12]\]; it has been studied in phase I--III clinical studies, and has been found to both lower LDL-C and reduce cardiovascular event rates \[[@CR13]--[@CR21]\]. In November 2016, clinical development of bococizumab was discontinued as a result of the emerging clinical profile observed from the SPIRE (Studies of PCSK9 Inhibition and the Reduction of vascular Events) phase III lipid-lowering program \[[@CR15], [@CR22]\]. The SPIRE program reported an unanticipated attenuation of LDL-C lowering over time, alongside a higher incidence of anti-drug antibodies (ADAs), and a higher rate of injection-site reactions than other agents in this drug class \[[@CR15], [@CR22]\]. Forty-eight percent of subjects in the SPIRE lipid-lowering studies had detectable ADAs to bococizumab and 29% also had neutralizing antibodies (NAbs) \[[@CR15]\]. However, all biologics have the potential to be immunogenic, and although humanizing reduces the risk of an immune response, the potential for immunogenicity still exists for both humanized and fully human antibodies \[[@CR23]--[@CR25]\].

During the SPIRE clinical trial program, approximately 16,000 subjects were treated with bococizumab \[[@CR14], [@CR15]\]. Given the high incidence of ADAs observed with bococizumab treatment \[[@CR15]\], and the potential for ADAs to persist within an individual, it was important to assess whether anti-bococizumab antibodies could cross-react with other anti-PCSK9 mAbs if subjects were subsequently treated with these approved anti-PCSK9 agents. Cross-reactivity between anti-bococizumab antibodies and either alirocumab or evolocumab could potentially alter the efficacy and/or safety profile of these mAbs. This study therefore sought to assess experimentally whether ADAs against bococizumab would cross-react with alirocumab or evolocumab. Moreover, this study outlines a novel approach for assessing cross-reactivity against a biotherapeutic within the same target class using a single assay approach. This approach is an adaptation of the specificity assessment outlined in the draft US Food and Drug Administration (FDA) guidance document \[[@CR26]\] and has been utilized to characterize gross epitope binding of ADAs (e.g., antibody--drug conjugates) \[[@CR27]--[@CR29]\]. While bococizumab was discontinued from clinical development, the conceptual approach taken to assess cross-reactivity may be applied to other biotherapeutics where cross-reactivity is a potential concern.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

Plasma samples from bococizumab-treated subjects enrolled in the SPIRE-HR study (ClinicalTrials.gov identifier NCT01968954) were analyzed for cross-reactivity to the anti-PCSK9 mAbs alirocumab and evolocumab. The study design and findings of the SPIRE-HR study have been published previously \[[@CR15], [@CR30]\]. Briefly, 711 statin (HMG-CoA reductase inhibitor)-treated subjects with primary hyperlipidemia or mixed dyslipidemia who were at high risk for cardiovascular events were randomized (1:1) and treated for 12 months with bi-monthly subcutaneous bococizumab (150 mg) or with placebo \[[@CR15], [@CR30]\]. All subjects provided written informed consent prior to participation in the study \[[@CR15], [@CR30]\]. The primary efficacy endpoint was percent change from baseline (%CFB) in LDL-C at Week 12 \[[@CR15], [@CR30]\]. In addition, the persistence of LDL-C response over the 12-month treatment period was also evaluated, as described elsewhere \[[@CR15]\].

Assessment of Immunogenicity {#Sec4}
----------------------------

Bococizumab immunogenicity (presence of ADA and NAb) was assessed at eight timepoints throughout the study from randomization (Day 1) to the follow-up visit at Week 58 (Day 407). ADAs to bococizumab were determined using a validated bridging electrochemiluminescent (ECL) immunoassay using MesoScale Discovery (MSD) technology and following a three-tiered testing strategy of screen, confirm specificity to bococizumab, and titer as previously described \[[@CR15]\]. Briefly, plasma samples, anti-bococizumab antibody-positive control (639.26G8.3D3.2C4 \[2C4\], Pfizer Inc, San Francisco, CA, USA), and a negative control plasma pool were incubated overnight with biotin (ThermoFisher Scientific, Waltham, MA)-labeled bococizumab and SULFO-TAG™ (Meso Scale Diagnostics, Rockville, MD)-labeled bococizumab. Following incubation, the ADA bridged with both biotin- and SULFO-TAG™-labeled bococizumab were captured on blocked MSD plates coated with streptavidin and detected using tripropylamine read buffer and an MSD imager \[[@CR15]\]. Samples confirmed as positive for bococizumab ADA were further characterized for NAb using a competitive ECL immunoassay and a two-tiered testing strategy of screen and titer, as previously described \[[@CR15]\]. ADA-positive samples had a titer ≥ 75 and NAb-positive samples had a titer ≥ 3. The overall inter-assay precision of the ADA assay was 1.32% for the positive control endpoint titer and 7.41% for the negative control. The inter-assay precision for the NAb assay was 10.0% for the positive control endpoint titer and ≤ 25.5% for the negative control.

Assessment of Cross-Reactivity {#Sec5}
------------------------------

The highest ADA titer sample from each bococizumab ADA-positive subject was selected and tested for cross-reactivity to alirocumab and evolocumab. If the highest titer sample for a given subject cross-reacted to alirocumab or evolocumab, additional samples (baseline and all other ADA-positive samples) were also analyzed for cross-reactivity.

Cross-reactivity to evolocumab or alirocumab was assessed by validating additional specificity tiers within the bococizumab ADA assay against each drug. These specificity tiers were performed in a similar manner to the bococizumab confirmatory assay, in which samples were diluted in the presence of excess bococizumab or buffer control. Inhibition of signal in the presence of spiked bococizumab versus buffer control confirms specificity of the response. Samples analyzed in the specificity assays for cross-reactivity were independently diluted in the presence of 40 µg/mL of alirocumab (Praluent^®^, Sanofi-Aventis, Bridgewater, NJ, USA) or evolocumab (Repatha^®^, Amgen, Thousand Oaks, CA, USA) and the subsequent assay signals were compared with samples diluted in buffer control to calculate percent inhibition. During method development, it was found that signal inhibition was saturated at 40 µg/mL for both alirocumab and evolocumab (data not shown) and this concentration was selected to be consistent with the concentration of bococizumab used in the confirmatory tier. Specificity cut-points for alirocumab and evolocumab were determined using 50 samples from placebo-treated subjects from the SPIRE-HR study performed over three independent runs and calculated based on a 99.9% confidence interval \[[@CR31]\]. The cross-reactivity cut-points (CR-CPs) for alirocumab and evolocumab were determined to be 18.0% and 16.9%, respectively. Bococizumab ADA-positive samples were classified as cross-reactive to alirocumab or evolocumab if the sample signal inhibition in the presence of either drug was greater than or equal to the corresponding CR-CP.

In order to determine the suitability of the method for assessing cross-reactivity between anti-PCSK9 mAbs, recombinant PCSK9 (rPCSK9, Pfizer Inc) was used as a surrogate cross-reactive positive control because an antibody-positive control capable of binding to all three anti-PCSK9 mAbs was not available. The selection of rPCSK9 was based on the fact that bridging ADA assay formats are susceptible to false positivity by multimeric soluble targets, which can mimic an ADA response by bridging the labeled drugs \[[@CR32]\]. PCSK9 is known to self-associate to form dimers and trimers \[[@CR33]\], and a concentration-dependent increase in the assay signal with an aggregated form of rPCSK9 was demonstrated in the bococizumab ADA screening assay (Fig. [1](#Fig1){ref-type="fig"}a), and this response was inhibited by all three anti-PCSK9 mAbs (Fig. [1](#Fig1){ref-type="fig"}b). In addition, only bococizumab was able to inhibit the signals generated by the two anti-bococizumab-positive controls (2C4 and 3 mAb pool \[637.23G8.H1, 637.10F2.E2.H4, and 2C4\], Pfizer Inc); signal inhibition was not observed with either alirocumab or evolocumab (Fig. [1](#Fig1){ref-type="fig"}b). Collectively, these observations demonstrate the specificity of the assay and that all three anti-PCSK9 mAbs can compete with rPCSK9 and, as such, rPCSK9 can be used as a surrogate positive control in the cross-reactivity assay.Fig. 1**a** Concentration-dependent bridging by rPCSK9 in the anti-bococizumab antibody assay, and **b** specificity of the assay controls to bococizumab, alirocumab, and evolocumab. *mAb* monoclonal antibody, *PC* positive control, *RLU* relative luminescence units, *rPCSK9* recombinant proprotein convertase subtilisin/kexin type-9

Immunogenicity Data Analysis {#Sec6}
----------------------------

Immunogenicity data were analyzed using descriptive statistics. Statistical calculations were performed using SAS^®^ software (version 9.3 or above; SAS Institute Inc., Cary, NC, USA).

Results {#Sec7}
=======

SPIRE-HR Immunogenicity Data {#Sec8}
----------------------------

In total, 356 subjects in the SPIRE-HR study received at least one dose of bococizumab, and 295 (82.9%) subjects completed the 52-week treatment period. The prevalence of pre-existing ADA to bococizumab was 0.9% for the bococizumab-treated subjects (3/338). None of these subjects showed a treatment-boosted ADA response (defined as a \> 3-fold dilution increase in titer from baseline) following bococizumab administration. In bococizumab-treated subjects, the overall incidence of ADA during the study was 44.0% (155/352), and 27.0% of subjects (61.3% ADA-positive subjects) also developed NAbs. The median (first quartile \[Q1\], third quartile \[Q3\]) time to first ADA and NAb detection was Day 168 (85, 174) and Day 166 (85, 170), respectively. However, ADAs and NAbs were first detected as early as Day 29. In addition, 67.1% (104/155) of ADA-positive subjects had ADAs that persisted for ≥ 16 weeks (≥ 112 days). The time course of ADA and NAb titers observed during the study is shown in Fig. [2](#Fig2){ref-type="fig"}. The median ADA and NAb titers ranged from 276 to 526 and from 8 to 12, respectively. The titers for the ADA samples tested for cross-reactivity to alirocumab or evolocumab are shown in Fig. [3](#Fig3){ref-type="fig"}. These samples had a median (Q1, Q3) titer value of 553 (212, 1833), representing samples collected from Day 29 to Day 415. In addition, 81 of the 155 highest-titer ADA-positive samples were also NAb-positive (52.3%) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Time course of **a** anti-bococizumab antibody titer, and **b** neutralizing antibody titer. *ADA* anti-drug antibody, *NAb* neutralizing antibodyFig. 3Anti-bococizumab antibody titers for samples tested for cross-reactivity by study day and by neutralizing antibody status. *ADA* anti-drug antibody, *NAb* neutralizing antibody

Analysis of Cross-Reactivity to Alirocumab and Evolocumab {#Sec9}
---------------------------------------------------------

Of the 155 ADA-positive subjects treated with bococizumab, cross-reactivity to alirocumab and evolocumab was detected in one subject (0.65%), as indicated by the percent signal inhibition above the CR-CP in the respective assays (Fig. [4](#Fig4){ref-type="fig"}a). This subject, who demonstrated cross-reactivity to both alirocumab and evolocumab, had neither pre-existing ADA to bococizumab nor pre-existing cross-reactivity to either drug at baseline. Analysis of all additional ADA-positive samples from this subject showed cross-reactivity to both alirocumab and evolocumab on Days 337 and 373 (Fig. [4](#Fig4){ref-type="fig"}b). However, cross-reactivity to either drug was no longer detected by Day 407, when the subject was still ADA-positive but NAb-negative. The cross-reactive signal inhibition ranged from 24.2 to 35.5% for either drug (Fig. [4](#Fig4){ref-type="fig"}b). This percentage signal inhibition was much weaker than the 72.8--75.2% signal inhibition observed for bococizumab assessed during the confirmation tier.Fig. 4In vitro cross-reactivity results to alirocumab and evolocumab for **a** all ADA-positive samples tested, and **b** the positive cross-reactive subject. *ADA* anti-drug antibody; *CR-CP* cross-reactivity cut-point

For the one subject who displayed in vitro cross-reactivity, anti-bococizumab antibodies were detected from Day 337 to the follow-up visit on Day 407. ADA responses were also characterized as neutralizing on Days 337 and 373 but not Day 407. In this subject, an initial robust reduction in LDL-C was demonstrated, with a Week 12 %CFB of − 82.2%, compared with mean %CFB of − 58.8% for ADA-negative subjects (Fig. [5](#Fig5){ref-type="fig"}). The LDL-C-lowering response in this subject who displayed cross-reactivity was slightly attenuated following the detection of ADA, which was further characterized as neutralizing.Fig. 5Time course of LDL-C response (%CFB) and antibody titer responses for the positive cross-reactive subject. *ADA* anti-drug antibody, *LDL-C* low-density lipoprotein cholesterol, *NAb* neutralizing antibody, *%CFB* percent change from baseline

Discussion {#Sec10}
==========

Within the past few decades, advances in the field of molecular biology have enabled antibody therapies to be designed and engineered towards target molecules of interest, in order to improve the management of therapeutic conditions such as cancer, inflammatory diseases, autoimmune diseases, and more recently dyslipidemia \[[@CR8], [@CR23], [@CR34]\]. Despite efforts to humanize the engineered protein, immunogenicity against mAbs is increasingly recognized as a possible mechanism to explain treatment failure or reduced efficacy. Bococizumab was terminated in late phase III clinical development, partly due to a high incidence of ADA and the attenuation of efficacy in subjects with high ADA titers \[[@CR15]\]. Although bococizumab is not approved for clinical use, approximately 16,000 patients were treated with bococizumab in the phase III studies \[[@CR14], [@CR15]\]. It was therefore important to determine whether anti-bococizumab antibodies in ADA-positive subjects would cross-react with marketed anti-PCSK9 mAbs (alirocumab or evolocumab) if subjects were subsequently treated.

Consistent with the pooled immunogenicity results reported for the six lipid-lowering SPIRE studies \[[@CR15]\], treatment-induced ADAs were observed in 44.0% of subjects in the SPIRE-HR study, and 27.0% of subjects also developed NAbs. In addition, 67.1% of ADA-positive subjects had ADAs that persisted for at least 16 weeks. Using samples from these bococizumab-treated subjects, we demonstrate experimentally that ADAs generated in response to bococizumab treatment are unlikely to cross-react with other anti-PCSK9 mAbs. Using a novel single-assay approach for assessing cross-reactivity against a biotherapeutic agent within the same target class, only one of the 155 ADA-positive subjects (0.65%) showed detectable cross-reactivity to alirocumab and evolocumab, and this cross-reactivity was both transient in nature and weak in signal. In the one subject who showed in vitro cross-reactivity to alirocumab and evolocumab, a slight attenuation in LDL-C response was observed, which coincided with the detection of NAbs to bococizumab. These results suggest that subjects who have previously received bococizumab may be treated for high LDL-C with an appropriate anti-PCSK9 mAbs, regardless of the presence of ADAs to bococizumab.

Although there was a need to investigate the possibility, cross-reactivity between anti-bococizumab antibodies and alirocumab or evolocumab was not anticipated, based on the differences in the structural properties of the anti-PCSK9 mAbs. As such, ADAs to bococizumab were not expected to recognize alirocumab or evolocumab, and this was confirmed by the present study. This low risk of clinically relevant cross-reactivity within the anti-PCSK9 therapeutic class is also consistent with the literature from the tumor necrosis factor (TNF) inhibitors \[[@CR35]--[@CR37]\]. Immunogenicity is a known contributing factor to the loss of clinical response to anti-TNF biologics \[[@CR38]--[@CR40]\]. However, studies have suggested that developing antibodies to one anti-TNF inhibitor does not necessarily translate to clinically relevant cross-reactivity, as a similar clinical response has been reported to a secondary TNF inhibitor for subjects who develop antibodies to a first TNF inhibitor compared with subjects who are treatment-naïve \[[@CR35], [@CR37]\].

While our findings showed a lack of cross-reactivity between anti-bococizumab antibodies and alirocumab or evolocumab, determination of ADA cross-reactivity is challenging. Immunogenicity data are highly dependent on the sensitivity, specificity, and drug tolerance of the assay used \[[@CR41]\], as well as other factors such as the study population or the 'cut-points' for defining a positive response. Therefore, the interpretation of cross-reactivity results should be made in the context of the assay capabilities and the experimental design. In assessing cross-reactivity using two independent methods for each biotherapeutic, a common cross-reactive positive control is needed to ensure similar method characteristics. For example, when assessing cross-reactivity for biosimilars, the positive control would be expected to cross-react with both the innovator and biosimilar drug to demonstrate and establish similar assay performance, if independent ADA assays for the innovator and biosimilar drug were used. When examining cross-reactivity across different biotherapeutics within the same class, a cross-reactive positive control may be limited or not feasible based on homology of the biotherapeutics. In the present study, the bridging ADA assay format allowed us to use the binding target as a surrogate cross-reactive positive control. This novel approach allowed assessment of cross-reactivity within the context of a single validated assay and helped minimize the problems associated with assessing cross-reactivity in separate assays. Thus, this method may be applicable to other biotherapeutics where cross-reactivity of ADAs may be a potential concern, especially for those within the same therapeutic class. One potential limitation of the present study is that evaluation of cross-reactivity was not conducted in a clinical switchover design. This assessment would require a clinical study where subjects who are ADA-positive to bococizumab were subsequently dosed with alirocumab or evolocumab, then efficacy and tolerability determined. However, such a switchover study would not be ethical given that bococizumab is no longer in clinical development \[[@CR22]\]. As noted earlier, studies within the TNF inhibitor class have indicated that ADAs do not necessarily limit the response to a second biologic within the same class \[[@CR35], [@CR37]\], and therefore clinically relevant cross-reactivity would not be anticipated for anti-PCSK9 mAbs.

Conclusion {#Sec11}
==========

A novel, single-assay approach was used to assess the potential cross-reactivity of anti-bococizumab antibodies to alirocumab and evolocumab. In subjects who previously developed ADAs to bococizumab, the likelihood of clinically relevant cross-reactivity to the two marketed anti-PCSK9 mAbs is remote or absent based on the low frequency of cross-reactivity observed in this study, which was both weak in signal inhibition and transient in nature.
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